Cargando…

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma

PURPOSE: In this study, the addition of ixazomib to lenalidomide maintenance post-autologous stem cell transplant (ASCT) in 64 patients with newly diagnosed multiple myeloma was evaluated on the basis of the observed benefit of lenalidomide-only maintenance in prior studies. PATIENTS AND METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Krina K., Shah, Jatin J., Feng, Lei, Lee, Hans C., Manasanch, Elisabet M., Olsem, Jasper, Morphey, Ashley, Huo, Xiao Jiao, Thomas, Sheeba K., Bashir, Qaiser, Qazilbash, Muzaffar H., Weber, Donna M., Orlowski, Robert Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365361/ https://www.ncbi.nlm.nih.gov/pubmed/34992070 http://dx.doi.org/10.1158/1078-0432.CCR-21-3420

Ejemplares similares

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
por: Hanna, Glenn J., et al.
Publicado: (2023)

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
por: Wang, Zhixiong, et al.
Publicado: (2020)

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2019)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2021)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022)

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
por: Grisham, Rachel N., et al.
Publicado: (2023)

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
por: Turner, Nicholas C., et al.
Publicado: (2021)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
por: O'Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
por: Biswas, Tithi, et al.
Publicado: (2022)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
por: Xia, Wei-Xiong, et al.
Publicado: (2021)

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
por: Chi, Ping, et al.
Publicado: (2022)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
por: Johnson, Melissa, et al.
Publicado: (2022)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
por: Majem, Margarita, et al.
Publicado: (2022)

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
por: Zhao, Jimmy L., et al.
Publicado: (2022)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
por: Zhou, Qing, et al.
Publicado: (2022)

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
por: Dziadziuszko, Rafal, et al.
Publicado: (2022)

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
por: Schuler, Martin, et al.
Publicado: (2022)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
por: Herrera, Alex F., et al.
Publicado: (2022)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
por: Yap, Timothy A., et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2021)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
por: Ascierto, Paolo A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_83hqgr4ddv5lcr9c5hdsam0l7e